Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

D0720000

Dexaméthasone 21-phosphate disodium salt

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Dexamethasone 21-phosphate disodium salt

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill) :
C22H28FNa2O8P
Numéro CAS:
2392-39-4
Poids moléculaire :
516.40
Beilstein:
6473066
Numéro CE :
219-243-0
Numéro MDL:
MFCD00079105
Code UNSPSC :
41116107
ID de substance PubChem :
329798630
Nomenclature NACRES :
NA.24
Le tarif et la disponibilité ne sont pas disponibles actuellement.

Qualité

pharmaceutical primary standard

Famille d'API

dexamethasone

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

[Na+].[Na+].[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1(F)[C@@H](O)C[C@@]4(C)[C@@]2([H])C[C@@H](C)[C@]4(O)C(=O)COP([O-])([O-])=O

InChI

1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15+,16+,17+,19+,20+,21+,22+;;/m1../s1

Clé InChI

PLCQGRYPOISRTQ-FCJDYXGNSA-L

Informations sur le gène

human ... NR3C1(2908)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dexamethasone sodium phosphate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1177000

Dexamethasone phosphate, United States Pharmacopeia (USP) Reference Standard

D0710000

Dexamethasone 21-acetate, European Pharmacopoeia (EP) Reference Standard

D0700000

Dexaméthasone, European Pharmacopoeia (EP) Reference Standard

D0718000

Dexamethasone pivalate, European Pharmacopoeia (EP) Reference Standard

Y0000511

Dexamethasone isonicotinate for impurity C identification, European Pharmacopoeia (EP) Reference Standard

Y0000538

Dexamethasone isonicotinate, European Pharmacopoeia (EP) Reference Standard

Y0001177

Dexaméthasone, European Pharmacopoeia (EP) Reference Standard

Y0001169

Dexamethasone acetate impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001477

Dexaméthasone 21-phosphate disodium salt, European Pharmacopoeia (EP) Reference Standard

Y0001593

Dexaméthasone, European Pharmacopoeia (EP) Reference Standard

1176506

Dexamethasone 21-acetate, United States Pharmacopeia (USP) Reference Standard

1176007

Dexaméthasone, United States Pharmacopeia (USP) Reference Standard

PHR1526

Dexaméthasone, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1527

Dexamethasone 21-acetate, Pharmaceutical Secondary Standard; Certified Reference Material

BP578

Dexaméthasone, British Pharmacopoeia (BP) Assay Standard

1177032

Dexaméthasone 21-phosphate disodium salt, United States Pharmacopeia (USP) Reference Standard

PHR1768

Phosphate sodique de dexaméthasone, Pharmaceutical Secondary Standard; Certified Reference Material

BP108

Dexaméthasone 21-phosphate disodium salt, British Pharmacopoeia (BP) Reference Standard

PHR1628

Dexamethasone Phosphate, Pharmaceutical Secondary Standard; Certified Reference Material

BP811

Dexaméthasone, British Pharmacopoeia (BP) Reference Standard

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H361d

Classification des risques

Acute Tox. 4 Oral - Repr. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 7

1 of 7

vibrant-m

P2810000

Prednisolone sodium phosphate

Betamethasone sodium phosphate United States Pharmacopeia (USP) Reference Standard

USP

1068004

Betamethasone sodium phosphate

Dexaméthasone Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1526

Dexaméthasone

Dexaméthasone European Pharmacopoeia (EP) Reference Standard

Y0001593

Dexaméthasone

Dexaméthasone United States Pharmacopeia (USP) Reference Standard

USP

1176007

Dexaméthasone

Dexaméthasone hydrosoluble suitable for cell culture, BioReagent

Sigma-Aldrich

D2915

Dexaméthasone hydrosoluble

Betamethasone European Pharmacopoeia (EP) Reference Standard

B1000000

Betamethasone

Veysel Nijat Baş et al.
European journal of pediatrics, 171(4), 735-736 (2011-12-29)
Iatrogenic Cushing syndrome may occur as an undesirable outcome of high-dose glucocorticoids treatments. This may also cause hypothalamus-hypophysis-adrenal axis suppression. While this situation may be caused more frequently with oral and topical glucocorticoid therapy, iatrogenic Cushing syndrome in childhood, caused
Weina Liu et al.
Neuroscience letters, 524(2), 119-123 (2012-07-21)
Prenatal exposure to glucocorticoids (GCs) leads to affective dysfunction in adulthood, which may be associated with the alterations in hypothalamic-pituitary-adrenal (HPA) axis. Physical exercise has been shown to ameliorate depressive symptoms. The objectives of present study were to investigate whether
Martin Gräber et al.
ACS chemical biology, 6(10), 1008-1014 (2011-07-30)
Phosphorylation-dependent protein binding domains are crucially important for intracellular signaling pathways and thus highly relevant targets in chemical biology. By screening of chemical libraries against 12 structurally diverse phosphorylation-dependent protein binding domains, we have identified fosfosal and dexamethasone-21-phosphate as selective
Mary J Berry et al.
Acta obstetricia et gynecologica Scandinavica, 92(7), 862-865 (2013-05-15)
Clinical practice guidelines for elective cesarean section at early-term gestation (37-38 weeks) recommend antenatal corticosteroids to reduce neonatal respiratory morbidity. However, the long-term health implications for offspring exposed to corticosteroids at term are unknown and may differ from the effects
Amy E Cohen et al.
Ophthalmology, 119(1), 66-73 (2011-11-26)
Determine safe, effective, iontophoretic dose(s) of EGP-437 (dexamethasone phosphate formulated for iontophoresis) in patients with noninfectious anterior uveitis; evaluate systemic drug exposures. Prospective, phase I/II, multicenter, double-masked, parallel group, randomized clinical trial. Forty outpatients with anterior uveitis. Forty of 42
Afficher tous les articles scientifiques apparentés

Questions

Reviews

No rating value

Active Filters

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique